Vamotinib（Cat No.:I043359）is a small-molecule inhibitor that targets the receptor tyrosine kinase Axl, which is involved in cell survival, migration, and angiogenesis. Overexpression of Axl is associated with various cancers, including lung, breast, and ovarian cancers. By inhibiting Axl, vamotinib disrupts cancer cell signaling, leading to reduced tumor growth and metastasis. Preclinical studies have shown its potential in combating drug-resistant cancers and improving treatment outcomes. Ongoing research is focused on evaluating vamotinib’s efficacy in clinical trials, particularly in combination therapies for more effective cancer treatment strategies.